Welcome to California COVID-19 Vaccination Program Friday Provider Office Hours




Friday, July 29, 2022



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at: https://eziz.org/covid/education/



If you have post-webinar questions, please email leslie.amani@cdph.ca.gov



Agenda: Friday, July 29, 2022

No.	Item	Speaker	Time (AM)
1	Welcome & Announcements	Leslie Amani (Moderator)	9:00 - 9:05
2	KidsVaxGrant 2.0	Nisha Gandhi (CDPH)	9:05 – 9:10
3	Vaccine Administration	Elizabeth Reosti (CDPH)	9:10 – 9:15
4	Clinical Update	Floria Chi, M.D. (CDPH)	9:15 – 9:25
5	Storage & Handling	Kate McHugh (CDPH)	9:25 – 9:30
		9:30 – 9:40	
6	Vaccine Management	Eric Norton (My Turn) and Maria Volk (CDPH)	9:40 - 9:50
7	Wrap Up & Resources	Leslie Amani (Moderator)	9:50 – 10:00
	Q&A		



Announcements

Leslie Amani, CDPH



CDPH Therapeutics Webinar for Providers

Please join CDPH for a new bi-weekly Provider series: Therapeutics

Attendees will hear CDPH Therapeutics subject matter experts discuss therapeutics equity, education, clinical updates, storage and handling, and other timely and relevant topics related to COVID-19 Treatments.

When: Monday, August 1, 2022 Time: 12PM – 1PM

Zoom registration link: Therapeutics Webinar for Providers



Archived: CDC COCA Call

Recommendations for the Novavax COVID-19 Vaccine Primary Series in Adults Ages 18 Years and Older

Centers for Disease Control and Prevention Center for Preparedness and Response



Recommendations for the Novavax COVID-19 Vaccine Primary Series in Adults Ages 18 Years and Older

Clinician Outreach and Communication Activity (COCA) Call Thursday, July 28, 2022



CDC COCA Call Slides 7.28.22

VA58 Trust & Safety Team Updates

The VA58 Trust & Safety Team reports on trending narratives about COVID-19, delivers biweekly briefings, and develops comprehensive resources to increase awareness around mis-, dis-, and mal-information, as well as the State's capacity to counter it.

BIWEEKLY BRIEFINGS

Biweekly briefings provide partners with the top COVID-19 vaccine mis/dis topics and trends, and invitees receive a copy of the report post-briefing.

To be added to the invite, email rumors@cdph.ca.gov.



RUMORS INBOX

The Rumors Inbox serves as a tip line for our partners to submit the COVID-19 rumors they're hearing online and within their communities to our team. We incorporate the submissions into our team's reporting.



Report COVID-19 Vaccine Rumors to:

rumors@cdph.ca.gov

RECENT TOPICS & RESOURCES

Mis/Dis/Mal-information: Study shows COVID-19 vaccination causes heavier menstrual bleeding **Trusted Resources:** <u>COVID-19 Vaccines for People</u> <u>Who Would Like to Have a Baby | CDC, COVID-19</u> <u>vaccines linked to small increase in menstrual cycle</u> <u>length | National Institutes of Health (NIH), COVID-19</u> <u>Vaccination Considerations for Obstetric–Gynecologic</u> <u>Care | ACOG</u>

Mis/Dis/Mal-information: False claims target Novavax vaccine after it receives EUA. Trusted Resources: Coronavirus (COVID-19) Update: FDA Authorizes Emergency Use of Novavax COVID-19 Vaccine, Adjuvanted | FDA, U.S. clinical trial results show Novavax vaccine is safe and prevents COVID-19 | National Institutes of Health (NIH)

Mis/Dis/Mal-information: Unvaccinated individuals will not suffer from myocarditis or pericarditis after a COVID-19 infection.

Trusted Resources: <u>Safety of COVID-19 Vaccines |</u> <u>CDC</u>, <u>COVID-19 Vaccine Effectiveness |</u> <u>CDC</u>, <u>Myocarditis and Pericarditis After mRNA COVID-19 Vaccination | CDC</u>, <u>Q&A: COVID-19, Vaccines, and</u> <u>Myocarditis | NIH COVID-19 Research</u>



Stay informed! Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!

Vaccinate All 58	California COVID-19 Vaccination Program						
Program Updates	Updates for Providers						
Program Enrollment							
My Turn Onboarding							
Vaccine Management							
Vaccine Administration	FAQs Provider Training Training Office Hours Calendar						
Reporting Requirements							
Archived Communications	Alerts:						
Patient Resources	Infant/Toddler Recommendations and Products						
Provider Support	 Guide of COVID-19 Vaccine Products Summary of Vaccines: Pfizer 6 months-17 years, Pfizer 6 months-4 years, Moderna 6 Months-17 years, and Moderna 6 months-5 years (CDPH) 						
COVID Call Center	Vaccine Management						
Email: Program Info Phone: (833) 502-1245 Hours: Mon-Fri, 8AM-6PM	 Receiving and Storing Novavax Vaccine - New Ordering and Distribution Cadenace Calendar - Updated Novavax Vaccine Storage and Handling Resources - New 						
Contact us for questions about the program or help with accessing documents.	Vaccine Administration Interim Clinical Considerations for Use of COVID-19 Vaccines (CDC) COVID-19 Vaccination Schedule (Timing Guide)-Updated for Novavax 						
myCAvax and My Turn	Spanish version: Calendario de la Vacuna COVID-19 (Guía de Tiempo)- Updated for Novavax						
Email: myCAvax Technical Support	 Children who transition from a younger to an older age group: Pfizer- BioNTech Moderna 						
MyTurn Onboarding, MyTurn Technical Support	Novavax Vaccine Administration Resources - New						
Phone: (833) 502-1245 Mon-Fri, 7AM-7PM Sat-Sun, 8AM-1PM	Planning Resources Preparing for Infant/Toddler Vaccinations Job Aid Planning for Under 5 Vaccinations Webinar Recording and Slides						
My Turn Clinic Translation Line:	Recommending COVID-19 Vaccination: Clinical Talking Points 6/17/22 Requesting COVID-19 Vaccination Staff						
(833) 980-3933 Mon-Fri: 8AM-8PM	Expanding Vaccination Capacity						
Sun-Sat: 8AM-5PM	Now Enrolling Providers of Pediatric Services						
Vaccines Manufacturer Contacts	 Find Information on How to Enroll Dispelling Provider Myths About Joining the California COVID-19 Vaccination Program 						
	Welcome VFC Providers Flyer VFC vs. COVID Programs						



EZIZ COVID Vaccine Administration Webpage

Novavax COVID-19 Vaccine Information

- <u>CDC Resources</u>
- Novavax COVID-19 Overview and Safety (CDC)
- <u>CDC Recommends Novavax COVID-19 Vaccine for</u> Adults
- EUA Information (FDA)
- EUA Fact Sheet for Providers Administering

Vaccine (FDA)

- EUA Fact Sheet for Recipients and Caregivers (FDA)
- Standing Orders (CDC)
- Vaccine Preparation & Administration Summary (CDC)
- Novavax COVID-19 Vaccine website



accinate

Updated with Novavax!

Ordering & Distribution Cadence Calendar

Vaccinate

Ordering & Distribution Cadence Calendar California COVID-19 Vaccination Program

Ancillary kits for all products will arrive within 24-48 hours of vaccine delivery and may arrive before vaccines.

For Providers

Week 1					Week 2				
Monday	Tuesday	Wednesday	Thursday	Friday	Monday	Tuesday	Wednesday	Thursday	Friday
Provider					Pfizer-Stan	dard			
Order (submit by 5pm)				Moderna/J&J/ Standard	Novavax–				
-				TPR-Pfizer		TPR-Pfizer			
		Limited					Pfizer–Standar	d	
		Catch-Up Orders* (submit by				Moderna/J8 Standard	J/Novavax-		
						and the second se			

Delivery windows are dependent on provider's days/hours of operation. Once submitted, orders cannot be cancelled.

Watch for emails regarding order confirmations, advance shipment notices of vaccine and ancillary kits, and temperature monitoring alerts. Add list of senders to your contacts or work with your IT staff to ensure emails are not filtered to Spam or Junk folders.

* Catch-up opportunity for urgent orders on Wednesday if Monday deadline is missed.

California COVID-19 Vaccination Program

IMM-1360 (7/27/22)

For Local Health Departments

Week 1				Week 2					
Monday	Tuesday	Wednesday	Thursday	Friday	Monday	Tuesday	Wednesday	Thursday	Friday
		LHD/MCE			Pfizer-Stan	dard			
Order (submit by 5pm)	Review Approval by 12pm			Moderna/J&J/N Standard	ovavax-				
⇒		CDPH Transmits to CDC & TPR		TPR-Pfizer		TPR-Pfizer			

Limited Catch-Up	LHD/MCE Review	LHD/MCE Approval by		Pfizer–Standar	d	
Orders* 12pm (submit by		Moderna/J& Standard	J/Novavax–			
5pm)		CDPH Transmits to CDC & TPR	TPR-Pfizer			

Delivery windows are dependent on provider's days/hours of operation. Once submitted, orders cannot be cancelled.

Watch for emails regarding order confirmations, advance shipment notices of vaccine and ancillary kits, and temperature monitoring alerts. Add list of senders to your contacts or work with your IT staff to ensure emails are not filtered to Spam or Junk folders.


* Catch-up opportunity for urgent orders on Wednesday if Monday deadline is missed.

California COVID-19 Vaccination Program

IMM-1360 (7/27/22)



Updated with Novavax! Vaccine Timing Guide: Pediatric/Adolescent/Adult



/accinate

58

cov	ID-19 Va	ccine	e Timir	ng− <i>F</i>	doles	ent/Adu	lt	Vaccinate All 58			
Routin	e Schedule]		
Age	Vaccine	Primary	Doses			Booster Doses					
12-17	Moderna– Adol/Adult	1st Dose	4-8 weeks*	2nd Dose							_
12+	Pfizer/ Adol/Adult	1st Dose	3-8 weeks*	2nd Dose	≥5 months	1st Booster Ages 12-17: Pfizer		2nd Booster Ages 50+: Moderna/Pfizer	t		Vaccinate All 58
18+	Moderna – Adol/Adult	1st Dose	4-8 weeks*	2nd Dose	≥5 months	18+: Moderna/ Pfizer (mRNA preferred) or J&J*	≥4 months	18-49: Not currently recommended. (If received J&J for	ter Doses		
18+	Janssen (J&J) Pfizer/Moderna preferred*	1st Dose	2	2 months				primary and 1st boost- er, may consider receiv- ing a 2nd booster of mRNA vaccine.)	looster		2nd Booster
18+	Novavax	1st Dose	3-8 weeks^	2nd Dose					s 12-17: r r/ erna	≥4 months	Ages 12-17: Pfizer 18+: Moderna/ Pfizer
 An <u>8-week interval</u> may be preferable for some people, especially for males 12-39 years. Although use of mRNA COVID-19 vaccines is preferred, the Janssen vaccine may be offered in <u>some situations</u>. View <u>Interim Clinical Considerations for Use of COVID-19 Vaccines</u> for details. Schedule is subject to change. 									via via srred) J*		
California	COVID-19 Vaccination	n Program					IMN	1-1396 (7/20/22) Page 2 of 3			
			18+	Novava			nd ose				
			-					e may be offered in <u>some situa</u> Is. Schedule is subject to chang			
			California C	OVID-19V	accination Progr	am				IMM-1396	(7/20/22) Page 3 of 3

Calendario de la Vacuna COVID-19: Novavax! Pediátrico/Adolescente/Adulto



Dosis

^ Un <u>intervalo de 8 semanas</u> puede ser preferible para algunas personas, especialmente para hombres de 12 a 39 años. Consulte las <u>Consideraciones Clínicas Provisionales para el uso de Vacunas Contra el COVID-19</u> para obtener más

Dosis semanas

Dosis

semanas

Pediátrico

información. El calendario esta sujeto a cambios California COVID-19 Vaccination Program

años

/accinate

Edad	Vacuna	Dosis Primarias	Dosis de Refuerzo			
12-17	Moderna– Adol/Adulto	1ra Dosis 4-8 semanas 2da Dosis			dulto	
12+	Pfizer/ Adol/Adulto	Tra Dosis 2da Dosis 25 meses	1er Refuerzo Edades 12-17: Pfizer	2do Refuerzo Edades 50+: Modema/Pfizer	etido de Refuerzo	
18+	Moderna- Adol/Adulto	1ra Dosis 4-8 semanas 2da Dosis 25 meses	18+: ≥4 meses Moderna/ Pfizer (ARNm preferido) o J&J*	18-49: Actualmente no recomendado. (Si recibió J&J para el		
18+	Janssen (J&J) Pfizer/Moderna preferido*	1ra Dosis ≥2 meses		refuerzo primario y el 1er refuerzo, puede considerar recibir un 2do refuerzo de la vacuna de ARNm.)	lefuerzo les 7: Pfizer	2do Refuerza Edades 12-12 Pfizer
18+	Novavax	1ra Dosis 3-8 semanas 2da Dosis			≥4 meses erna m rido)	18+: Moderna/ Pfizer
Aunque Considera cambios.	e se prefiere el uso de v aciones Clinicas Provis	uede ser preferible para algunas personas, especiali vacunas ARNm COVID-19, la vacuna Janssen se pue ionales para el Uso de Vacunas Contra el COVID-19	de ofrecer en <u>algunas situaciones</u> . Co para obtener más información. El cal	nsulte con las endario esta sujeto a		
alifornia	COVID-19 Vaccination		IMM-1396	iS (7/25/22) Pagina 2 of 3		
		* Aunque se prefiere el uso de vacun	as ARNm COVID-19, la vacuna Jansse	en se puede ofrecer en <u>algunas</u>	situaciones. Consulte	con las
		Consideraciones Clinicas Provisional	es para el Uso de Vacunas Contra el C	OVID-19 para obtener más info	ormación. El calendario	o esta sujeto a
		cambios.				

IMM-1396S (7/25/22) Página 1 de 3

CDPH IZB Program and Product Training

IMMUNIZATION BRANCH

Updated with

Novavax!

Vaccination Program	
Training	Training and Resources
Program Enrollment	Required Training for Participation in the California COVID-19
Vaccine Management	Vaccination Program
Vaccine Administration	Providers and key practice staff storing, handling, managing, or administering vaccines must complete the
Reporting Requirements	required training to meet federal and state program requirements.

Program Training

This training prepares sites to incorporate program requirements into clinic protocols and identifies key resources for use on the job. Organization & Location Coordinators must complete the required program training in myCAvax during enrollment but may access the lessons below. Review times are approximate.

Interactive Lessons	Organization* Coordinator	Location† Coordinator
Program Requirements (15 mins) (PDF)	✓	\checkmark
Orders and Distribution (5 mins) (PDF)	-	\checkmark
Storage and Handling (15 mins) (PDF)	-	\checkmark
Vaccine Management (10 mins) (PDF)	-	\checkmark
VaccineFinder (5 mins) (PDF)	~	\checkmark
Organization Coordinators complete Section A of the provider enrollm mplementing vaccination program requirements for their provider orga t Location Coordinators complete Section B (location enrollment) and a	anization.	·
provider location.		

COVID-19 Vaccine Product Training

This training shows staff how to prepare, administer, store, and handle COVID-19 vaccine products and report adverse events to VAERS. To prepare in advance of initial vaccine shipments, print and review summary sheets only for products your location will be ordering. Review times vary by learner role & technical experience.

fizer-BioNtech	Location Coordinator	Vaccinator	Provider
 Vaccine Preparation & Administration Ages 6M-4Y Ages 5-11 Ages 12+ (PDF) Mixing Diluent & Vaccine (PDF) Storage & Handling: Ages 6M-4Y Ages 5-11 Ages 12+ (PDF) 	~	V	~
Delivery Checklist (PDF)	\checkmark	-	-
oderna	Location Coordinator	Vaccinator	Provider
 Vaccine Preparation & Administration & video Ages 6M-5Y Ages 18+ (PDF) Storage & Handling: 	~	\checkmark	~
Ages 6M and older (PDF)			
anssen (J&J)	Location Coordinator	Vaccinator	Provider
Vaccine Preparation & Administration (PDF)	~	~	~
Storage & Handling (PDF)	\checkmark	-	-
ovavax	Location Coordinator	Vaccinator	Provider
	 ✓ 	\checkmark	1
 Vaccine Preparation & Administration (PDF) 	v	v	•

COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 07/29/2022
- Currently in its 82nd iteration!

🕻 Q: When will the Novavax vaccine by available in My Turn?

A: The My Turn team expects Novavax to be available in My Turn in late August, 2022. In the meantime, clinics can use <u>vaccines.gov</u> to allow the public to search for and make appointments. Please use these instructions to <u>enter location information manually</u> or use <u>file upload</u>.

Q: Can COVID-19 vaccine Providers submit Medi-Cal reimbursement claims for individuals 6 months and older?

A: Yes. COVID-19 vaccine Providers may now submit Medi-Cal reimbursement claims for individuals 6 months and older. For further information, please visit the <u>Department of</u> <u>Health Care Services (DHCS) COVID-19 Vaccine for Children 6 Months and Up News Flash</u> and <u>DHCS COVID-19 Medi-Cal Response Page</u>.

California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers. Providers may also visit <u>California COVID-19 Vaccination Program</u> for information and updates.

Directions: Click on a category to be directed to related FAQs.

Contents

New and Updated FAQs	2
Pediatric Providers	3
Vaccine Program Management	4
Provider Enrollment	5
Ordering	5
Distribution/Redistribution	5
Vaccine Administration	6
Additional/Booster Doses	9
Vaccine Storage & Handling	10
Inventory	11
Reporting	11
Billing & Reimbursement	12
Communication Resources	13

Provider FAQs on EZIZ, Updated Weekly



Pfizer COVID-19 Vaccine Updates & Trainings

Date & Time (linked)	Password			
<u>Tuesday, August 02 - 12PM</u>	HmHmJjPT536			
<u>Wednesday, August 03 - 9AM</u>	SXbpceVW332			
<u>Thursday, August 04 - 9AM</u>	XBdEXrVn792			
Tuesday, August 09 - 12PM	yqJDdwJD628			
<u>Wednesday, August 10 - 9AM</u>	24pfRM9yn4W			
<u>Thursday, August 11 - 9AM</u>	V2HfiYJd3m8			
<u>Tuesday, August 16 - 12PM</u>	mpShpynK233			
More sessions listed! NOTE: All times listed here are PDT.				

Audience:

Providers and immunization staff

Session Topics Include:

- New vaccine presentation (Maroon Cap) for individuals 6 months through 4 years of age
- FDA approvals, authorizations including recent authorizations
- Gray Cap, Comirnaty®
- Use of each vaccine presentation, including storage, handling, preparation, and administration

Moderna Infant/Toddler Vaccine Video Trainings

moderna

Link to Video Resources





How to Withdraw a 0.25mL dose: Infant/Toddler 6 months-5 years

How to Withdraw a 0.5mL Dose for Pediatrics 6 Years-11Years

US-COV-2200159 06/2022



COVID-19 Vaccination Program Webinars and Training for Providers

Week of August 1, 2022

Note: Calendar subject to change

	Monday 8/1	Tuesday 8/2	Wednesday 8/3	Thursday 8/4	Friday 8/5
myCAvax, My Turn, and Combined Office Hours and Events	<u>CDPH Therapeutics</u> <u>Webinar for Providers</u> 12:00 pm – 1:00 pm	Pfizer BioNTech COVID-19 Vaccine Training & Education* 12:00 pm – 1:00 pm PW: HmHmJjPT536	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: SXbpceVW332	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: XBdEXrVn792	Provider Office Hours 9:00 am – 10:00 am
* Pfizer topics vary by day and include the latest information about use of each vaccine presentation, including storage, handling, preparation, and administration; recent medical updates and FDA authorizations, healthcare provider resources, and a Q&A session.					
View On Demand	 Intro to My Turn Onboarding (v. 1/4/22) Latest Features in myCAvax (*Requires myCAvax Login) 			Provider 101 Account Enrollment: Section A: Organization <u>Application</u> (v. 10/21/21)	

• myCAvax Release Notes for LHJs and CDPH Users

COVID-19 Crucial Conversations Archived Webinars

(*Requires myCAvax Login)

and Slides

- Provider 101 Account Enrollment: Section B: Location Application (v. 10/21/21)
- Provider Office Hours and MCE Office Hours Archived <u>Sessions</u>

Help

Website: <u>www.eziz.org/covid</u>, <u>FAQs</u> General email: <u>covidcallcenter@cdph.ca.gov</u> CDPH Provider Call Center: 1-833-502-1245, 8am-6pm


Latest Features in My Turn

(*Requires My Turn Login)

My Turn email: <u>myturnonboarding@cdph.ca.gov</u> myCAvax Help Desk Email: <u>myCAvax.HD@accenture.com</u> Phone: (833) 502-1245



August is National Immunization Awareness Month!





KidsVaxGrant 2.0

Nisha Gandhi, CDPH





PHC* KidsVaxGrant 2.0 Launching Monday, August 1!



- The California Department of Public Health has appropriated approximately \$10 million to support KidsVaxGrant 2.0.
- Providers can receive up to \$35,000 to support eligible pediatric providers administering the COVID-19 vaccine.





PHC* KidsVaxGrant 2.0 Funding Opportunities

Eligibility:

- Providers serving pediatric populations who've placed at least one complete order of an infant/ toddler COVID-19 vaccine and are newly enrolled in the California COVID-19 Vaccine Program (myCAvax) may receive \$10K to support enrollment and launching a vaccination center. Those that enroll in myCAvax from December 17, 2021 to October 14, 2022, will qualify.
- Providers serving pediatric populations vaccinating infants/toddlers against COVID-19 already enrolled in the California COVID-19 Vaccine Program (myCAvax), who are expanding operating hours by a minimum of 25 hours, may be eligible for \$25K, per site.
 - Expanded hours must be outside of normal or existing clinic hours and must be completed within 120 days of the application's approval (not retroactive).

Providers serving pediatric populations that were previously awarded a KidsVaxGrant are eligible to apply for KidsVaxGrant 2.0!



PHC KidsVaxGrant

Vaccine Administration Data


Elizabeth Reosti, CDPH



Vaccine Administration Summary

as of July 25, 2022


accinate



Public Dashboard

78,476,295 Total Doses Administered:

Daily Doses Administered: Statewide



Month of Date Administered



Trends in Vaccine Administration

as of July 25, 2022

New Eligibility Groups Driving Demand

- First doses among Under 5
- First boosters among 5-11-year-olds
- Second boosters among 50+ year-olds

50-64 18-49 300K 288,524 12-17 5-11 254,509 Under 5 250.265 250K 240,613 82.239 210.620 66,956 78,544 58,777 200K 54.506 150K 80,569 63.031 58.254 72,416 54,520 100K 48,778 54,759 50,688 43,492 54,674 50K 26,488 26.814 16.080 28,688 22.790 34,804 32,756 29,352 26,440 23 361 0K June 12, 2022 June 19, 2022 June 26, 2022 July 3, 2022 July 10, 2022 Week Start Date Percent change from - 2% - 4% - 12% + 37% previous week 65+ - 15% - 12% - 7% +51%50-64 + 48% 18-49 - 7% - 4% - 11% +26% 12-17 - 10% - 7% - 12% +24% 5-11 - 12% - 8% - 14% + 18% - 33% +26% Under 5 +32%

Weekly Doses Administered by Age Group

Age Group

65+

FDA NEWS RELEASE

Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech COVID-19 Vaccines for Children Down to 6 Months of Age

For Immediate Release: June 17, 2022

291.080

80,948

77.378

52,268

39.357

July 17, 2022

+1%

- 2%

- 4%

- 5%

- 5%

+1%

+ 34%

California and the Nation

as of July 18, 2022

California

Total Doses Administered 78,156,577

195,678 per 100K

Infant/Toddlers with 1+ dose 120.4K

5,370 per 100K

Nationwide

Total Doses Administered 601,479,801

182,543 per 100k

Infant/Toddlers with 1+ dose 544.1K


3,157 per 100k




California and the Nation

as of July 25, 2022

Primary Series Complete by Age



Primary Series Complete by Race & Ethnicity




CA Nationwide



Infant/Toddler Vaccination Rates

as of July 25, 2022

Lower vaccination rates among Black and Latinx children after the first five weeks





Infant/Toddler Vaccination Trends

as of July 25, 2022

Weekly New Under 5 Initiating Primary Series by VEM: Statewide

Modest uptake in Under 5 population, higher among Quartile 3 and Quartile 4






Infant/Toddler Vaccination Trends

as of July 25, 2022

Slower roll out over the first 36 days of eligibility for the youngest eligibility group







as of July 25, 2022

Latest Metrics

78.5 Million doses administered
291K doses administered in previous week (+1% point change)
18K new Infant/Toddler recipients (-17% point change)

System Updates

- Vaccination data for children under 5 years of age added to all dashboards
- 4th doses included in overall dose count, but not currently displayed in immunization status



Clinical Update Floria Chi, M.D., CDPH



Novavax COVID-19 Vaccine Updates


• 7/13/2022:

 Food and Drug Administration (FDA) Emergency Use Authorization granted for Novavax


- 7/19/2022:
 - Advisory Committee on Immunization Practices (ACIP) and Centers for Disease Control and Prevention (CDC) recommend use as primary series in adults 18+
- 7/22/2022:
 - Approval by Western States Scientific Safety Review Workgroup (WSSSRW)

Novavax COVID-19 Vaccine Schedule

People who are **NOT** moderately or severely immunocompromised



People who ARE moderately or severely immunocompromised





Mixed Primary Series

- Mixed primary series is not authorized
- If mixed series is inadvertently administered, the series is considered complete, and no doses need to be repeated.
- Exceptions
 - ° Same vaccine unavailable
 - First dose unknown
 - Contraindication
 - ° These do not need to be reported to VAERS.

Coadministration

- In general, COVID-19 vaccines may be administered without regard to timing of other vaccines.
 - 🗹 Same day
 - Any time before
 - Any time after
- Routine administration of all age-appropriate doses of vaccines simultaneously is recommended for people for whom no specific contraindications exist at the time of the healthcare visit.


Coadministration: Orthopox Vaccine

If orthopoxvirus vaccine administered first: Might consider waiting 4 weeks before receiving a Moderna, Novavax, or Pfizer-BioNTech vaccine

If Moderna, Novavax, or Pfizer-BioNTech administered first:

No minimum interval necessary before receiving orthopoxvirus vaccination for prophylaxis in the setting of an outbreak







Interim Clinical Considerations for Novavax COVID-19 Vaccine ACIP Meeting, July19, 2022 Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States

Outline


• COVID-19 in pregnancy

 ${\rm \circ}\, {\rm Risks}$ to mother and baby

- COVID-19 vaccine safety in pregnancy
- Benefits of COVID-19 vaccination in pregnancy
 - ° Benefits to mother and baby
- Passing on immunity to infants



COVID-19 in Pregnancy Associated with Adverse Events



accinate COVID-19 Infection Among Hospitalization Pregnant Women

COVID-19 in Pregnancy

- Rates of hospitalization, O2 requirement, and ICU admission are greater in COVID-19
 positive pregnant patients than COVID-19 positive non-pregnant women.
- Increased risk of Cesarean section and preterm delivery in COVID-19 positive patients
- CDC analysis of ~400,000 women aged 15-44 with symptomatic COVID-19 showed an increased risk of ICU admission, invasive ventilation, ECMO (extracorporeal membrane oxidation), and death among pregnant versus nonpregnant women.
- Unvaccinated pregnant women represented 77.4% of infections, 90.9% of admissions, and 98% of ICU admissions in a study performed in Scotland comparing vaccinated and unvaccinated pregnancies.

40

Are COVID-19 Vaccines Safe in Pregnancy?

Pregnant women were excluded from the initial randomized control trials (RCTs) of the mRNA COVID-19 vaccines.

Despite this exclusion, there were several pregnancies in both the placebo and vaccinated groups of the Pfizer/BioNTech, Moderna, and AstraZeneca clinical trials.

<u>Outcome</u>: No difference in the rate of pregnancies or miscarriages between the vaccinated and placebo groups.

41

Are COVID-19 Vaccines Safe in Pregnancy?

Table 4


Summary of maternal delivery and pup data from the female rats in the delivery cohort administered control (saline) or BNT162b2.

	Control (saline)	BNT162b2
Delivery Cohort (n) ^a	22	21
Gestation Length (days)	$22.1\pm0.4^{\rm b}$	22.0 ± 0.7
Number of implantation sites	14.3 ± 2.2	14.2 ± 2.2
Pups delivered per litter (PND 0)	13.3 ± 2.5	13.1 ± 3.1
Number live pups at birth (mean/litter)	13.0 ± 2.5	13.0 ± 3.1
Live Birth Index ^c	98 %	99.3 %
Pup Viability Index (PND 0–4) ^d	99 %	98.9 %
Pup Weaning Index (PND 4–21) ^{e,f}	99.4 %	100 %
Pup Mortality (PND 0-21)	10	5
Pup body weight on PND 4 (g) ^f	9.60 ± 1.25	9.75 ± 1.31
Pup body weight on PND 21(g) ^f	54.75 ± 4.07	$\textbf{55.23} \pm \textbf{2.71}$

Both Moderna and Pfizer have toxicology data on safety of COVID-19 vaccines in pre-clinical trials showing no adverse effects on female reproduction, fetal or embryonic development or postnatal development.

Are COVID-19 Vaccines Safe in Pregnancy?





UK study showed no difference in the rate of adverse outcomes on multiple measures (preterm birth, small birth weight for gestational age (SGA), congenital malformations, all-cause hospitalizations, and infant death) between vaccinated and unvaccinated pregnant women.

COVID-19 Vaccination in Pregnancy



COVID-19 vaccination* among pregnant people is associated with



about 60% reduced risk of COVID-19 hospitalization in babies younger than 6 months old

People who are pregnant, may become pregnant, or are breastfeeding should get vaccinated against COVID-19

bit.ly/MMWR7107e3

Test registre, user-control data among strates at 20 performs to optimis in 17 state during full 1, 2011 during h1, 2019. ¹ Completed a 2-does primary orbits (2010) To nuccessition series during programs data. 1 Select programs and data 2-doesing as before during all.

MMWR



Halasa NB et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19– Associated Hospitalization in Infants Aged 6 Months — 17 States, July 2021–January 2022. MMWR Morb Mortal Wkly Rep. 2022;71(7):264-270

COVID-19 Vaccination in Pregnancy in the Delta & Omicron Periods

Subgroup	Case Infants no. of vaccinated r	Control Infants mothers/total no. (%)	Effective	ness of Maternal Vaccin % (95% Cl)	ation
Overall effectiveness of maternal vaccination	87/537 (16)	147/512 (29)			52 (33 to 65)
Timing of vaccination					
During first 20 wk of pregnancy	46/496 (9)	62/427 (15)			38 (3 to 60)
After 20 wk of pregnancy	31/481 (6)	79/444 (18)		D	69 (50 to 80)
Delta-predominant period	14/181 (8)	61/216 (28)		—— — —	80 (60 to 90)
Vaccinated during first 20 wk of pregnancy	8/175 (5)	22/177 (12)			68 (19 to 87)
Vaccinated after 20 wk of pregnancy	5/172 (3)	37/192 (19)		D	88 (68 to 96)
Omicron-predominant period	73/356 (21)	86/296 (29)			38 (8 to 58)
Vaccinated during first 20 wk of pregnancy	38/321 (12)	40/250 (16)			25 (-26 to 56)
Vaccinated after 20 wk of pregnancy	26/309 (8)	42/252 (17)			57 (25 to 75)
Type of hospital admission					
ICU	11/113 (10)	147/512 (29)		D	70 (42 to 85)
Non-ICU	76/424 (18)	147/512 (29)		_	47 (25 to 62)
			-25 0 25	50 75 100	
			Vaccine Ef	fectiveness (%)	

Figure 3. Effectiveness of Maternal Two-Dose mRNA Vaccination against Hospitalization for Covid-19 among Infants, Stratified According to Vaccination Timing, Variant, and Type of Admission.

The delta-predominant period was defined as July 1, 2021, to December 18, 2021. The omicron-predominant period was defined as December 19, 2021, to March 8, 2022. The timing of maternal vaccination was based on the date of receipt of the second dose of a two-dose series of an mRNA Covid-19 vaccine during pregnancy. Gestational age was missing for 3 infants who had been born to vaccinated mothers with known timing of the second dose; for these infants, classification of vaccination timing was based on a gestational age of 40 weeks. For 16 infants who had been born to mothers who had been fully vaccinated during pregnancy, dates of vaccination were not available to determine the vaccination timing during pregnancy. Vaccine effectiveness was calculated as (1 – adjusted odds ratio) x 100, where the odds ratio is the odds of maternal vaccination among mothers of case infants as compared with control infants. The widths of the confidence intervals have not been adjusted for multiplicity and should not be used in place of a hypothesis test.

- Overall maternal vaccine effectiveness (VE) was 52% in preventing COVID-19 hospitalization of infants <6 months of age.
- Maternal VE was 70% in preventing ICU admission of infants <6 months of age.

COVID-19 Vaccination in Pregnancy in the Delta & Omicron Periods





Figure 2. Clinical Severity of Covid-19 as Indicated by Outcomes among Case Infants, According to Maternal Vaccination Status.

Critical Covid-19 was defined as Covid-19 leading to life-supporting interventions (i.e., noninvasive mechanical ventilation [bilevel positive airway pressure or continuous positive airway pressure], invasive mechanical ventilation, vasoactive infusions, or extracorporeal membrane oxygenation) or to death. An infant could have been included in more than one outcome category. Two infants who had been born to unvaccinated mothers (2 of 450 infants [<1%]) received extracorporeal membrane oxygenation. An additional 2 infants who had been born to unvaccinated mothers (2 of 442 infants [<1%]) died; among the 450 infants who had been born to unvaccinated mothers, 8 had mothers for whom data on hospital discharge were not available. ICU denotes intensive care unit. Infants born to unvaccinated mothers had more severe COVID-19 outcomes including ICU admission, critical COVID-19, and the need for life-supporting interventions than infants born to vaccinated mothers.

Passing Immunity from Mother to Baby



 Comparison of antibody titers in infants born to vaccinated mothers
 versus those born to
 SARS-CoV-2 infected
 mothers (20-32 weeks)
 showed higher anti-S

 Persistence of antibodies continued out to 6 months of age

47

Strategies

- Encourage prenatal healthcare providers to:
 - Talk to their patients about COVID-19 vaccines as early as possible
 Provide COVID-19 vaccines in obstetric clinics
- Public messaging surrounding the benefits of COVID-19 vaccination in pregnancy
 - $_{\odot}$ Decrease complications
 - Passing of immunity
- Continue to update messaging as new data become available
 - \circ Role of boosters
 - Risk of new variants



Resources for Pregnant People

- American College of Obstetrics and Gynecology (ACOG)
 - FAQs for Patients on COVID-19 Vaccine in Pregnant and Lactating People
 - COVID-19 Vaccines and Pregnancy: Conversation Guide for Clinicians | ACOG
- CDC Information about COVID-19 Vaccines for People Who are Pregnant or Breastfeeding
 - MotherToBaby experts are available to answer questions in English or Spanish, Monday-Friday 8am-5pm at 1-866-626-6847 or online.
- CDC Myths and Facts about COVID-19 Vaccines
 - Includes information about fertility, menstrual cycles
- CDC Poster: COVID-19 and Pregnancy
- CDPH <u>Communications Toolkit for Pregnancy and COVID-19 Vaccine</u>



Communication Tools



NEW PODCAST EPISODE

Episode 320: Vaccinations for Infants, Toddlers & During Pregnancy: A COVID-19 Discussion with Dr. Erica Pan

Super Mamás

Super Mamas Spotify Podcast



CDPH Facebook Live

Facebook Live



SF Chronicle



Vaccinate


Storage & Handling

Kate McHugh, CDPH



Novavax Storage and Handling

- 10 dose multi-dose vials
- Cap color: Royal Blue
- Refrigerated storage (2°C to 8°C) until expiration date
 - The first vials to be shipped will have a nine-month expiry date
 - Expiration dates can be found on: Novavax Expiry Website
- Do not freeze
- Injection volume: 0.5 mL
- No diluent required
- Storage after puncture
 - Hold the vial between 2° to 25°C (36° to 77°F) for up to 6 hours
 - Discard the vial 6 hours after the first puncture
- EUA: Novavax HCP Fact Sheet 07132022 (fda.gov)





Receiving and Storing Novavax

Includes:

- Fact Sheet
- Vaccine Expiration Dates
- Critical Notifications
- Storage Unit Organization
- Error Reduction
- Instructions

Receiving & Storing Novavax Vaccine California COVID-19 Vaccination Program

Upon delivery, sites assume responsibility for storing vaccines in temperature-controlled environments. Never reject vaccine shipments.

Novavax COVID-19 Vaccine, Adjuvanted | Fact Sheet

- Product (Vial NDC 80631-100-01) is available in 100-dose carton; adult ancillary kit ships within 24-48 hours of vaccine and includes PPE.
- Authorized under EUA as a 2-dose primary series for ages 18Y+. Do not dilute.
- Vaccine contains SARS-CoV-2 spike protein and Matrix-M adjuvant; adjuvants are incorporated into some vaccines to enhance the immune response of the vaccinated individual (read more).
- Distribute Fact Sheet for Recipients & Caregivers prior to vaccination.
- Vaccine ships like other routine refrigerated temperatures between 2° to 8°C (36° to 46°F).
- Store unpunctured multi-dose vials in a refrigerator between 2° to 8°C (36° to 46°F) until expiration.
 Protect from light. DO NOT FREEZE.
- Hold punctured vials between 2° to 25°C (36° to 77°F) for up to 6 hours then discard.
- Apply storage and handling labels to cartons to prevent administration and handling errors.
- Dispose of cooler and packing materials; there is no return option available for refrigerated shippers.
- CDC's Preparation & Administration Summary (TBD), <u>Storage & Handling Summary</u>, and <u>Standing</u> <u>Orders</u>.
- See CDC <u>COVID-19 Vaccine Product Guide</u> (details about vaccine, kits, dimensions, PPE & needles; to be updated for Novavax) or <u>CDPH chart</u>.

Vaccine Expiration Dates

No expiration date is printed on vial or carton. To find expiration date by lot number, <u>check online</u>. Do not use vaccine after the expiration.

Do not dispose of vaccine without ensuring the expiration date has passed. As expiration dates draw near, check with the manufacturer for any extensions, or use CDC's <u>COVID-19 Vaccine Lot Number and Expiration</u> <u>Date Report</u>. (This site requires you to <u>register</u> before accessing the information.) As expiration dates are extended, use CDC's <u>expiration date tracker</u> to record updated expiration dates.

Critical Notifications

Coordinators receive emails regarding order confirmations, advance shipment notices of vaccine and kits, and temperature monitoring alerts. Add <u>critical senders</u> to your contact list, or work with IT staff to have these senders added to your organization's email whitelist, to ensure emails are not filtered to Spam or Junk folders.

California COVID-19 Vaccination Program

IMM-1436 (7/21/22)

IMM-1436 (7/25/22)



is at top of cooler).

ad the monitor.

expired vaccine.

original packaging to

and handling errors.

ature excursions in transit

Vaccinate

ALL 58

Pfizer Pediatric 5 Years -11 Years Expiry

- Pfizer vaccines for ages 5 years -11 years currently being shipped have an expiry date of the end of September.
- Pfizer will not be shipping vaccines that have less than 30 days to expiry.
- Currently, there are no plans for a shelf-life extension in the immediate future.
 - If your Pfizer Pediatric 5 years -11 years expires, please discard it.
- CDPH will share more information, once received.





- Pfizer expiry lookup tool released
- Website: lotexpiry.cvdvaccine.com

Pfizer-BioNTech COVID-19 Vaccine Expiry

To find the expiration date for the Pfizer-BioNTech COVID-19 vaccine lot number, enter the lot number found on the vial or the carton.

To ensure proper storage and handling, please see <u>cvdvaccine.com</u>.

United States of America	
Enter Lot# (e.g. #AB0000)	Subm
pecial characters (commas, /, *, &) are	



Transport of COVID-19 Vaccines

- Job Aid: <u>Transporting Vaccines</u>
- Ensure you are using a properly conditioned transport container and a digital data logger.
- Providers should ensure vaccine stayed within the temperature range during transport prior to using the vaccine.
- If using vaccine at off-site clinics, keep vials in the conditioned transport container until ready for use

° Many manufacturers don't have data for excursions above ~85-90°F



Reporting & Missed Vaccination Opportunities & Wastage

Updated

Reporting Doses Spoiled, Expired, or Wasted

California COVID-19 Vaccination Program

Waste is expected and may be unavoidable in any vaccination program. Wastage reporting helps CDC better understand how much inventory is in the field and where the greatest needs for inventory exist to minimize the potential waste of vaccine. Follow <u>CDC's Toolkit</u> and <u>CDC summary guidance</u> to maximize vaccination opportunities while minimizing waste.

Key Points

- · Remove spoiled, expired, or wasted vaccines from the storage unit immediately
- Do not return nonviable vaccines to the manufacturer or McKesson
- Report nonviable doses in myCAvax before disposal
- · Follow these instructions to report nonviable doses and dispose of vaccines

Program Requirements

Enrolled providers must document and track vaccine wastage as part of routine vaccine inventory
management activities and report the number of doses of COVID-19 vaccine and adjuvants that were
unused, spoiled, expired, or wasted as required by the relevant jurisdiction.

Reporting Requirements

Login to myCAvax and click Vaccine Inventory – Waste to report spoiled, expired, or wasted vaccines before disposing of vaccines. Include product, lot number, and expiration date.

Spoiled Vaccines

Consistent and accurate temperature monitoring should minimize spoiled vaccines. Vaccines are considered spoiled if manufacturers determine vaccines were exposed to out-of-range temperatures and may not be used. If the vaccine is determined to be non-viable, vaccine must be reported as "spoiled" and properly disposed of. Vaccines could spoil as a result of the following conditions:

- · data logger indicates that storage unit temperatures are out of the recommended range
- storage unit temperatures are not monitored
- failure to store vaccines properly upon receipt
- vaccines spoiled during transfer
- natural disaster, power outage, or mechanical failure

California COVID-19 Vaccination Program

IMM-1347 (7/21/22)

Vaccinate

ALL 58

Updated

Missed Vaccination Opportunities &

Wastage



California COVID-19 Vaccination Program


Never miss a vaccination opportunity because of fear of vaccine wastage! Do your best to follow clinical and inventory management best practices for vaccination to maximize vaccinations and minimize dose wastage where possible.

Key Points

Vaccine wastage is expected, may be unavoidable, and will even increase as vaccine rollout continues because

- · more providers, including smaller provider sites, are now receiving vaccine;
- · vaccine continues to be available only as multi-dose vials; and
- · vials must often be punctured without using the full number of doses printed on the label.

Never Miss a Vaccination Opportunity



California COVID-19 Vaccination Program


IMM-1379 (7/20/22)

Job Aid: Reporting Doses Spoiled, Expired, Wasted

Job Aid: Missing Vaccination Opportunities & Wastage 57

Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Vaccine Management

Eric Norton, My Turn, and Maria Volk, CDPH



Monkeypox Vaccine & the My Turn Outbreaks Approach

With increased interest in expanding My Turn beyond COVID-19 and flu to create a solution for disease outbreaks happening across CA, and especially with Monkeypox being a recent driver for this expansion, we are evaluating the development of an outbreak approach.

Initial Monkeypox functionality will launch in My Turn on August 15th.



Novavax Update

The My Turn team is prioritizing the launch of My Turn Outbreaks and will switch focus to adding Novavax to the system after the Monkeypox functionality is released.

We expect Novavax to be available in My Turn starting in late August.



Get Ready for My Turn Release 29!

New updates for My Turn Public Clinic launched July 27th.

Clinic



- Removing flu zero out flu vaccine supplies to remove nasal spray and flu shot tags
- In-home vaccination and transportation page updates to reflect guidance for under 5 patients
- ✓ [Delivery] Update error messaging for better user experience and accessibility
- [Continued] Failure Point Notification setting up monitoring tools throughout system to flag (potential) issues

✓ [SMS/Email] Opt-out on the Walk-In flow
 ✓ [Vaccine Inventory] Entering Lot Numbers correctly
 ✓ [CAIR2] Concatenate "Cross Street 1" and "Cross Street 2"

Public



COVID-19 Interactive Eligibility Chart

A sint

Everyone aged 6 months and older is eligible for the primary series of a COVID-19 vaccine. Booster and Additional doses are available to eligible patients who have completed a primary series of COVID-19 vaccine. Specific COVID-19 vaccine brands and doses have different timing requirements.

My Turn Public is launching an Interactive Eligibility Chart so that patients can see a quick view of their options.

_				
Enter your age	5 years ~	Lookup		
	Pfizer	Moderna	Johnson & Johnson	
Primary Yes 3 dose series		Yes 2 dose series	No	
Additional	Yes	No	No	

NOTE: Booster and Additional doses are available to eligible patients who have completed a primary series of a COVID-19 vaccine. For Pfizer and Moderna, the primary series is two doses, and for Johnson & Johnson it's a single dose. Some patients benefit from receiving a 2nd dose 8 weeks after the 1st dose, however, all patients must wait at least 20 days (Pfizer) or 27 days (Moderna).

Other factors may impact eligiblity, please talk to your provider.



Vaccine Inventory Tooltip Update: Entering Lot Numbers



When editing or creating a new vaccine inventory record, only enter **up to 10 alphanumeric characters including dashes** in the **Lot** field on the New Vaccine Inventory screen. *A space is not considered a valid character.*

	YCAVOX Hor	me	Clinics Vaccine Invento	orv Appointments	Add Walk-In Appointme	nt Bulk Walk-In Unioa	×	More 🗸
				New Vaccine Inve	ntory: New Vaccine			
O Need H	Help? Please see the Clinic Ma	nager -					-	
			Asset Information				- 18	
	ne Inventory		*Asset Name		Status 🚯		- 18	
Rec	cently Viewed 🔻 🕴	J			None	•	- 18	
3 items • Upda	ated 18 hours ago		* Vaccine Type		* Account			\$\$ ▼
A	Asset Name 🗸 🗸	Bra	COVID-19		aracters, including dashes. (xXx-	Q		~
1 N	Noderna (6-11) - B1234	Mo	View all dependencies * Brand	12489)	*Lot 1		1	
2 N	Noderna (6-11) - A1234	Mo	Moderna	•			М	
3 Ir	nfant/Toddler Moderna - C1	Mo	View all dependencies Presentation		* Expiration Date		М	
4 ir	nfant/Toddler Moderna - B1	Mo					M	
5 Ir	nfant Toddler Moderna	Mo			C	ancel Save & New	Save	
6 N	Noderna - A1234	Moderna	l os Anaeles	County Vaccin A1234	10.000	5/23/2022	2. 12:00 PM	



Novavax Ordering

- Providers can order Novavax in myCAvax!
- The minimum Standard Order is 100 doses.
- Providers can opt out of ancillary kits.
- LHJs that offer local redistribution will be opening up for small orders as they receive product.



Ordering & Distribution Cadence Calendar



California COVID-19 Vaccination Program

Ancillary kits for all products will arrive within 24-48 hours of vaccine delivery and may arrive before vaccines.

For Providers

Monday	Tuesday	Wednesday	Thursday	Friday	Monday	Tuesday	Wednesday	Thursday	Friday
Provider					Pfizer-Star	dard			1999
Order (submit by 5pm)				Moderna/J&J/ Standard	Novavax–				
-				TPR-Pfizer		TPR-Pfizer			
		Limited					Pfizer–Standar	ď	
		Catch-Up				Madaaa /19			
		Orders* (submit by				Moderna/J8 Standard	J/NOVavax-		
		5pm)				TPR-Pfizer			
	Delivery windows	are dependent on	provider's days	hours of operat	ion. Once subr	nitted, orders	cannot be cance	lled.	
		regarding order con <u>s t</u> o your contacts o	Contraction of the second second						toring alerts
	* Catch-un onno	ortunity for urgent o	orders on Wed	nesday if Monday	deadline is m	issed			



APPENDIX



myCAvax – Known Issues - Updated 7/22

≻_[™] Known Issues

Small Order Fulfillment Method Blank?

- We are working to correct an issue where the 'Fulfillment Method' is not correctly defaulting based on a product's small order/TPR availability and the LHD's small order product settings
 - If the product is eligible for TPR orders but your LHD is not offering fulfillment locally, the 'Fulfillment Method' for the small order should default to 'Redistributor'
 - If the product is NOT eligible for TPR orders but your LHD is offering fulfillment locally, the 'Fulfillment Method' for the small order should default to 'Local'
 - If the product is eligible for TPR orders and your LHD is offering fulfillment locally, the 'Fulfillment Method' for the small order should default to 'Local'

စ်္- Workaround/Next Steps

- ✓ Fix: 8/11/2022
- No Workaround. Your LHD will handle the fulfillment method at the time of the order's review



Slide Icon Key

Icon	Meaning
	This is to label slides that are referencing upcoming or existing functionality and how to use it in the system.
<u> </u>	This is to label slides that include important system reminders.
Ş	This is to label slides that include tips and best practices to improve your system experience.



Release Roadmap

RECENTLY DEPLOYED July 14th (R28.0)

Orders

- Order Fulfillment Updates to allow multiple lots and general UI enhancements
- Allow LHD users update additional details on the Shipment Records (i.e., quantity, product, expiration date, etc.)
- ✓ Validate Shipping Hours
- ✓ Set Flags for Temporary Closure on Vaccine Order Review page

Account

- ✓ Temporary Closure for Location Accounts
- ✓ Add Calibration Expiration date to Storage Unit List

Community

- ✓ Update Thermometer Type options
- ✓ Add Data Logger as Shipment Incident Type
 Site Visits
- ✓ Provider Category
- ✓ VFC Assigned Pin

Other

✓ Put LHD Dashboard on LHD Homepage

IN PROGRESS August 11th (R29.0)

Orders

✓ Monkeypox ordering

Account

- ✓ Provider initiated Disenrollment
- ✓ Disenrollment due to inactivity

Site Visits

✓ Update Users who are Recipients in Site Visit Confirmation Email Notifications

Other

 ✓ Add 'Shipment Incident' as a new status reason for Order Holds on an account

UPCOMING September 8th (R30.0)

Account

 Smarty Street Enhancements: Address validation on existing accounts

Community

✓ Unified Login Experience

Site Visits

✓ Follow Up Actions



My Turn Public Product Roadmap

RECENTLY DEPLOYED July 7th (R28.4)

CURRENT July 27th (R29)

Release 28.4

- Moderna Pediatric 6-years-11-years two dose series
- Moderna Adolescent 12-years-17years two dose series
- In-home vaccination and transportation page updates to reflect guidance for under 5 patients
- [Continued] Failure Point Notification – setting up monitoring tools throughout system to flag (potential) issues
- [Continued] Analysis Consider walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

Release 29

- Moderna Pediatric/Adolescent 6-17
 Additional Dose rollout
- Translations refresh
- Update eligibility chart to CDC link
- Display number of locations on Select a Location page
- Pfizer Infant/toddler (6 months 4 years) second dose reminder communications
- [Testing] Custom flows for vaccine type
- [Delivery] Failure Point Notification setting up monitoring tools throughout system to flag (potential) issues
- [Testing] Consider walk-in and bulk upload appointments for clinic's Public Portal capacity and availability

UPCOMING August 24th (R30)

Release 30

- ✓ SMS opt in
- [Testing] Custom flows for vaccine type
- [Delivery] Update error messaging for better user experience and accessibility
- [Continued] Failure Point Notification setting up monitoring tools throughout system to flag (potential) issues
- [Testing] Consider walk-in and bulk upload appointments for clinic's Public Portal capacity and availability



My Turn Clinic Product Roadmap

RECENTLY DEPLOYED
July 7 th (R28)

CURRENT July 27th (R29)

Release 28.4

- ✓ Moderna Pediatric 6-years-11-years two dose series
- years two dose series
 - Add Vaccine Supply & Inventory
 - ✓ Bulk Walk-In Upload
 - Clinic Creation Setup
 - ✓ Walk-in Flow Update
 - ✓ Vaccine Administrator Flow Update
 - ✓ Single/Bulk Update
 - Appointment/IIS Tab Filter Update
 - Dashboard Homepage Update

Release 29

- [Walk-In] Adding tool tips to the Homeless questions
- ✓ Moderna Adolescent 12-years-17- 🖌 ✓ [Vaccine Inventory] Entering Lot Numbers correctly
 - [CAIR2] Concatenate "Cross Street 1" and "Cross Street 2"
 - [Clinic Creation] Infant/toddler Pfizer (6m-4yrs) checkbox visible
 - [IIS Tab] Update filters to mimic the Appointment tab Filters
 - Moderna 6m-17years Additional Dose
 - ✓ Walk-In flow
 - Vaccine Administration flow
 - Single/Bulk Edit update
 - Clinic Creation Setup
 - ✓ Vaccine Supply & Inventory
 - Bulk Walk-In Upload
 - Appointment/IIS Tab Filters

UPCOMING August 24th (R30)

Release 30

- ★ ✓ [SMS/Email] Opt-out on the Walk-In flow
 - [Walk-In Flow] Make the second Homelessness question optional
 - Monkey Pox Flow
 - Clinic Creation Setup
 - ✓ Walk-In flow
 - Vaccine Supply & Inventory
 - Appointment/IIS tab filters
 - Vaccine Administration flow
 - ✓ Single Edit

accinate





Additional Support


Type of	Support	Description	Updated 6.6.22
	COVID-19 Provider Call Center	 The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical provider their COVID-19 response, specifically addressing questions about State program requirements, enrollm distribution, including the Vaccine Marketplace. Email: covidcallcenter@cdph.ca.gov 	
		Phone: (833) 502-1245, Monday through Friday from 8AM–6PM	
	Enrollment Support	For Provider enrollment support, please contact myCAvax Clinic Operations at	
		Email: myCAvaxinfo@cdph.ca.gov	
		Dedicated staff provide up-to-date information and technical support on the myCAvax system.	
لباح	myCAvax Help Desk	Email: myCAvax.HD@Accenture.com	
\Box		 Phone: (833)-502-1245, option 3, Monday through Friday 8AM–6PM 	
		For training opportunities: https://eziz.org/covid/education/	
	My Turn Clinic Help Desk	For onboarding support (those in the process of onboarding): <u>myturnonboarding@cdph.ca.gov</u>	
		For technical support with My Turn Clinic for COVID-19 and flu vaccines: <u>MyTurn.Clinic.HD@Accentur</u> (833) 502-1245, option 4: Monday through Friday 8AM–6PM	<u>e.com</u> or
		For job aids, demos, and training opportunities: flu at <u>https://eziz.org/covid/myturn/flu/</u> and COVID at <u>http</u>	<u>s://eziz.org/covid/myturn/</u>
	Archived Communications	For archived communications from the COVID-19 Provider Call Center about the California COVID-19 V visit Website: <u>EZIZ Archived Communications</u> 	accination Program





Latest Updates







Pfizer Gets Approval for Booster Ages 5-11

Learn More



Read the Latest



Test to Treat Program

Learn More

Get the Facts



Producing Safe and SMART **Events**

See the Playbook





Updated Masking Guidance



See the Latest



Daily CDPH News Release



See the Latest

When to Mask

need to wear a mask.

Find out when and where you may still

ୁତ

Health

Quick Tips for

Fighting

COVID-19

-

Contact Tracing

What to expect if you are notified by a contact tracer that you've been exposed to COVID-19.

Learn About Contact Tracing



Tested Positive?

Stay home, self-isolate and watch for symptoms if you test positive for COVID-19.

Get Instructions



Choosing Your Mask

An effective mask has both good fit and filtration, and can help prevent you and others from getting COVID-19.

Learn More

ø

Protect & Prevent

Get all the information you need to protect yourself and others from COVID-19.

Slow the Spread



COVID-19 Vaccines

Schedule an appointment to get vaccinated if you're age 5+.

Learn About Vaccines



Recently Exposed?

Wear a well-fitting mask around others, and follow quarantine and testing recommendations.

See Instructions



Travel Tips

Get all the information you need before you take your next trip.

See CDC Guidelines

Testing Get the latest on who should get tested and where.

Get Tested

X

•

COVID-19 Treatments


Learn how treatments could help you recover faster or protect you from getting COVID-19.

Learn About Treatments



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Thank you!



Monday

Provider Therapeutics Webinar Next session: Monday August 1, 12PM My Turn and myCAvax Office Hours

Next session: Monday, August 8, 12PM

Friday

Provider Office Hours

Next session: Friday, August 5, 9AM



Thank you to Provider Office Hours' Planning Team: Leslie Amani, Rachel Jacobs, Blanca Corona, and Selena Polston